D. Western Therapeutics Institute (FRA:6DW) Cyclically Adjusted PS Ratio: (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6DW D. Western Therapeutics Institute Inc FRA:6DW
29 GF Score
Price €0.37
GF Value €0.33
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


D. Western Therapeutics Institute  (FRA:6DW) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


D. Western Therapeutics Institute Cyclically Adjusted PS Ratio Related Terms


D. Western Therapeutics Institute Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute Cyclically Adjusted PS Ratio Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.24 21.93 11.20 0.00 0.00

D. Western Therapeutics Institute Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.05 9.75 0.00 0.00 0.00

FRA:6DW vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D. Western Therapeutics Institute Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio falls into.


FRA:6DW
29GF Score
D. Western Therapeutics Institute Inc FRA:6DW
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

D. Western Therapeutics Institute Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

D. Western Therapeutics Institute's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 is calculated as:

For example, D. Western Therapeutics Institute's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

D. Western Therapeutics Institute Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.007 98.100 0.008
201603 0.024 97.900 0.028
201606 0.009 98.100 0.010
201609 0.009 98.000 0.010
201612 0.015 98.400 0.017
201703 0.009 98.100 0.010
201706 0.015 98.500 0.017
201709 0.033 98.800 0.038
201712 0.017 99.400 0.019
201803 0.016 99.200 0.018
201806 0.019 99.200 0.022
201809 0.025 99.900 0.028
201812 0.026 99.700 0.029
201903 0.084 99.700 0.095
201906 0.027 99.800 0.031
201909 0.028 100.100 0.032
201912 0.040 100.500 0.045
202003 0.024 100.300 0.027
202006 0.024 99.900 0.027
202009 0.024 99.900 0.027
202012 0.031 99.300 0.035
202103 0.024 99.900 0.027
202106 0.029 99.500 0.033
202109 0.030 100.100 0.034
202112 0.026 100.100 0.029
202203 0.029 101.100 0.032
202206 0.024 101.800 0.027
202209 0.024 103.100 0.026
202212 0.031 104.100 0.034
202303 0.020 104.400 0.022
202306 0.020 105.200 0.021
202309 0.025 106.200 0.027
202312 0.023 106.800 0.024
202403 0.020 107.200 0.021
202406 0.021 108.200 0.022
202412 0.000 110.700 0.000
202503 0.014 111.100 0.014
202506 0.010 111.700 0.010
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is D. Western Therapeutics Institute (FRA:6DW) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of €0.37 is trading 10.9% above its estimated GF Value™ of €0.33. GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.

Key valuation signals for FRA:6DW:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.33 vs. price of €0.37 (10.9% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the FRA:6DW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


D. Western Therapeutics Institute Business Description

Other Exchanges 4576:Japan
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
29GF Score

Get the complete analysis for FRA:6DW

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price
€0.33
GF Value